Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine
Figure 2
Pharmacokinetics of oral TAC versus i.v. 5-azacitidine in C57BL/6 mice. (a) Mean plasma concentration versus time for tri-acetyl azacytidine (TAC) (β²) and resultant ACT (β) in nontumor bearing mice after a 38βmg/kg dose of oral TAC. Mean plasma concentration versus time for ACT in nontumor bearing mice after 25βmg/kg ACT i.v. (). Error bars indicate standard deviation. (b) Noncompartmental plasma pharmacokinetic parameters for azacitidine (ACT) and tri-acetyl azacitidine (TAC). AUClast values are mean (standard error). NEβnot estimated. NCβnot calculated.
